Cancer Cell SiHa Research Articles

Solid-state synthesis of novel anticancer drug eutectic mixture; anticancer, physical and thermal studies

Green, solvent-free synthesis is adopted for a new pharmaceutical drug-drug eutectic with the utmost 100% yield. The synthesized eutectic mixture is significant for anticancer activity. The mandate of clinical tests could be avoided as selected nicotinamide, salicylamide, p-aminoacetinilide and benzanilide are known drugs. The compositional behaviors and established phase diagrams infer the formation of eutectics. The thermal behaviors of eutectics are studied using DSC. Further studies of eutectics are targeted for their biological applications, particularly for cell viability and anticancer activity against SiHa cancer cells where eutectic of benzanilide-salicylamide system infers its potential applicability for anticancer activity.

The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.

Recently developed vaccines for the SARS-CoV-2 virus utilize endogenous production of the virus' spike protein (SP), allowing the host to develop an immune response. As a result of the novelty of this virus and its vaccines, little is known overall about the potential effects of the SP on the pathogenesis of neoplasia, either from vaccination or from infection. This study was designed to investigate whether SARS-CoV-2 SP has any direct effect on SiHa cervical cancer cells. The effects of SARS-CoV-2 SP on cervical cancer cell proliferation and apoptosis were investigated by using clonogenic cell survival assay, quick cell proliferation assay, and caspase-3 activity kits in a widely-used cervical cancer cell line, SiHa. RT-PCR and immunohistochemistry were also performed to determine the potential molecular mechanisms. The growth and proliferation of SiHa cancer cells were inhibited by SARS-CoV-2 SP. SARS-CoV-2 SP also induced apoptosis in SiHa cancer cells. The anti-proliferative effect of SARS-CoV-2 SP on SiHa cancer cells was associated with the up-regulation of the anti-proliferative molecule p53. The pro-apoptotic effect of SARS-CoV-2 SP on SiHa cells was associated with the up-regulation of the pro-apoptotic molecule TRAIL. SARS-CoV-2 SP inhibits the growth of cervical cancer via up-regulation of p53 and TRAIL. Further studies are needed to elaborate on the potential effects of the SARS-CoV-2 SP on other cancer cell lines and normal physiological cell lines for comparison.

In silico screening, synthesis, characterization and biological evaluation of novel anticancer agents as potential COX-2 inhibitors.

Cyclooxygenase enzyme is frequently overexpressed in various types of cancer and found to play a crucial role in poor prognosis in cancer patients. In current research, we have reported the new COX-2 inhibitors for cancer treatment using computer-aided drug design and experimental validation. A total of 12,795 compounds from the different databases were used to screen against the COX-2 enzyme. It perceived three new compounds with better binding affinity to the enzyme. Afterwards, physicochemical properties and in silico bioactivity were assessed for efficacy, safety, and structural features required for binding. The molecules were synthesized and confirmed by spectroscopic techniques. Later on, molecules were evaluated for their anti-cancer activity using MCF-7, MDA-MB-231 and SiHa cancer cell lines. Compound ZINC5921547 and ZINC48442590 (4a, and 4b) reduced the MCF-7, MDA-MB-231, and SiHa cells proliferation potently than parent compounds. The PG-E2 estimation shown, both compounds act through the COX-2 PGE2 axis. Compound 4a and 4b block the cell cycle at G1-S phase and induce cancer cell death. We concluded that compounds 4a and 4b effectively promotes cancer cell death via COX-2 PGE2 axis, and further in vivo studies can be evaluated for development in both compounds as anticancer agents. The compilation of this information will help us to generate better outcome through robust computational methods. The high-quality experimental results may pave the way for identifying effective drug candidates for cancer treatment.

LY6K depletion modulates TGF-β and EGF signaling.

Lymphocyte antigen 6 complex locus K (LY6K), a glycosylphosphatidylinositol-anchored protein, plays a dynamic role in cancer metastasis. In the current study, we deciphered the effects of LY6K on transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) signaling through clathrin- and caveolin-1 (CAV-1)-mediated endocytosis. Analysis of the TCGA and GTEx dataset were performed to explore the expression and survival of LY6K in cancer patients. Short interfering RNA (siRNA) was used to knockdown the expression of LY6K in human cervical cancer patients. The effect of lack of LY6K on cell proliferation, migration, and invasion was performed, and RT-qPCR and immunoblotting were performed to identify LY6K-affected TGF-β and EGF signaling pathways. Additionally, Immunofluorescence (IF) and transmission electron microscope (TEM) were performed to identify the role of LY6K in CAV-1- and Clathrin-mediated endocytosis. Lymphocyte antigen 6 complex locus K expression level is elevated in higher grade cervical cancer patients correlating with poor overall survival, progression-free survival, and disease-free survival. LY6K-depletion in HeLa and SiHa cancer cells suppressed EGF-induced proliferation and TGF-β-enhanced migration and invasion. Both TGF-β receptor-I (TβRI) and EGF receptor (EGFR) localized at the plasma membrane regardless of LY6K expression, and LY6K bound TβRI irrespective of the presence of TGF-β; however, LY6K did not bind EGFR. LY6K-depleted cells showed impaired Smad2 phosphorylation upon TGF-β treatment and lower proliferation rates following long-term treatment with EGF. We revealed the atypical movement of TβRI and EGFR from plasma membrane upon ligand stimulation in LY6K-depleted cells and an impaired movement of the endocytic proteins clathrin and CAV-1. Our study demonstrates the key role of LY6K in both clathrin- and CAV-1-mediated endocytic pathways regulated by TGF-β and EGF, and it suggests a correlation between LY6K overexpression in cervical cancer cells and poor overall survival.

Abstract LB010: LY6K depletion modulates TGF-β and EGF signaling

Abstract Lymphocyte antigen 6 complex locus K (LY6K), a glycosylphosphatidylinositol-anchored protein, plays a dynamic role in cancer metastasis. In the current study, we deciphered the effects of LY6K on transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) signaling through clathrin- and caveolin-1 (CAV-1)-mediated endocytosis. LY6K expression level is elevated in higher grade cervical cancer patients correlating with poor overall survival, progression-free survival, and disease-free survival. LY6K-depletion in HeLa and SiHa cancer cells suppressed EGF-induced proliferation and TGF-β-enhanced migration and invasion. Both TGF-β receptor-I (TβRI) and EGF receptor (EGFR) localized at the plasma membrane regardless of LY6K expression, and LY6K bound TβRI irrespective of the presence of TGF-β; however, LY6K did not bind EGFR. LY6K-depleted cells showed impaired SMAD2 phosphorylation upon TGF-β treatment and lower proliferation rates following long-term treatment with EGF. We revealed the atypical movement of TβRI and EGFR from plasma membrane upon ligand stimulation in LY6K-depleted cells and an impaired movement of the endocytic proteins clathrin and CAV-1. Subsequently, transmission electron microscopy showed no clathrin and CAV-1-coated vesicles in LY6K-depleted cells. Our study demonstrates the key role of LY6K in both clathrin- and CAV-1-mediated endocytic pathways regulated by TGF-β and EGF, and it suggests a correlation between LY6K overexpression in cervical cancer cells and poor overall survival. Citation Format: Young Yang, Sujeong Park. LY6K depletion modulates TGF-β and EGF signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB010.

Comparative In Vitro Anticancer Study of Cisplatin Drug with Green Synthesized ZnO Nanoparticles on Cervical Squamous Carcinoma (SiHa) Cell Lines.

In this article, we aimed to develop a unique treatment approach to cure cervical cancer without harming healthy normal cells and overcome the limitations of currently available therapies/treatments. Recently, chemotherapeutics based on metal oxides have gained attention as a promising approach for treating cancer. Herein, ZnO nanoparticles were synthesized with the leaf extract of Azadirachta indica. These green synthesized ZnO nanoparticles were used for a cytotoxic study on the cervical squamous carcinoma cell line SiHa and murine macrophage cell line RAW 264.7. Moreover, a hemolytic assay was performed to check the biocompatibility of ZnO nanoparticles. The biosynthesized ZnO nanoparticles were labeled as L1, L2, L5, and L10 nanoparticles. Various assays like crystal violet, MTT assay, and AO/PI dual staining method were performed to assess the anticancer potential of ZnO. The concentration of ZnO nanoparticles was taken in the range of 100-250 μg/mL in the in vitro anticancer study on SiHa cancer cell lines. The findings of the MTT assay revealed that biosynthesized ZnO nanoparticles exhibited significant cytotoxicity against SiHa cancer cell lines dose-dependently at two incubation times (24 and 48 h). Also, a decrease in cell viability was observed with an increased concentration of ZnO. The IC50 values obtained were 141 μg/mL for L1, 132 μg/mL for L2, 127 μg/mL for L5, and 115 μg/mL for L10 nanoparticles. In addition, cisplatin drug (10 μg/mL) was also used to compare the anticancer activity with the biosynthesized L1, L2, L5, and L10 nanoparticles. The results of the crystal violet assay and AO/PI dual staining method revealed that morphological changes like cell shrinkage, poor cell adhesion, and induction of apoptosis occurred in the SiHa cancer cell lines. Furthermore, the stability of the ZnO nanoparticles at physiological pH has been assessed by recording the UV-visible spectrum at various pH values. Hence, the overall findings suggested that biosynthesized ZnO nanoparticles can be utilized for cervical squamous cancer treatment in addition to the current treatment strategies/techniques.

Investigation of the Antineoplastic Effects of 2-(4-Chlorophenyl)-13α-Estrone Sulfamate against the HPV16-Positive Human Invasive Cervical Carcinoma Cell Line SiHa.

Cervical carcinoma is one of the most frequent malignant gynecological cancers in women of reproductive age. Because of the poor tolerability of currently available chemotherapeutic agents, efforts have been focused on developing innovative molecules, including steroids, that exert antineoplastic effects with a better safety profile. In addition to their endocrine properties, certain estrogens exhibit additional biological activities, such as antiangiogenic and anticancer effects. Based on previous studies, the antineoplastic properties of 13α-estrone sulfamate derivatives (13AES1-3) were investigated, and the mechanism of action for the most promising compound 13AES3 was explored. Based on their effects on the viability of different human adherent gynecological cancer cells, the SiHa cervical cell line was used for mechanistic experiments. The most active analog 13AES3 was shown to exert considerable proapoptotic effects, as evidenced by a colorimetric caspase-3 assay and fluorescent double staining. It also elicited antimigratory and anti-invasive effects in a concentration-dependent manner, as evidenced by wound healing and Boyden chamber assays, respectively. Regarding their mechanism of action, 13AES derivatives were shown to inhibit tubulin polymerization, and computer simulations provided a possible explanation for the importance of the presence of the chlorophenyl ring on the estrane skeleton. 13AES3 is considered to be the first 13α-estrone derivative with a significant antineoplastic potency against SiHa cancer cells. Therefore, it might serve as a valuable lead molecule for the design of anticancer agents targeting cervical carcinomas.

Downregulation of miR-193a/b-3p during HPV-induced cervical carcinogenesis contributes to anchorage-independent growth through PI3K-AKT pathway regulators.

Cervical cancer is caused by a persistent infection with high-risk types of human papillomavirus(HPV) and an accumulation of (epi)genetic alterations in the host cell. Acquisition of anchorage-independent growth represents a critical hallmark during HPV-induced carcinogenesis, thereby yielding the most valuable biomarkers for early diagnosis and therapeutic targets. In a previous study, we found that miR-193a-3p and miR-193b-3p were involved in anchorage-independent growth. This study aimed to delineate the role of miR-193a/b-3p in HPV-induced carcinogenesis and to identify their target genes related to anchorage-independent growth. Cell viability and colony formation were assessed in SiHa cancer cells and HPV-16 and -18 immortalized keratinocytes upon miR-193a/b-3p overexpression. Both microRNAsreduced cell growth of all three cell lines in low-attachment conditions and showed a minor effect in adherent conditions. Online target-predicting programs and publicly available expression data were used to find candidate messenger RNA(mRNA) targets of miR-193a/b-3p. Seven targets showed reduced mRNA expression upon miR-193a/b-3p overexpression. For three targets, Western blot analysis was also performed, all showing a reduced protein expression. A direct interaction was confirmed using luciferase assays for six genes: LAMC1, PTK2, STMN1, KRAS, SOS2, and PPP2R5C, which are phosphatidylinositol 3-kinase/protein kinase B(PI3K-AKT) regulators. All six targets were overexpressed in cervical cancers and/or precursor lesions. Together with an observed downregulation of phosphorylated-AKT upon miR-193a/b-3p overexpression, this underlines the biological relevance of miR-193a/b-3p downregulation during HPV-induced cervical carcinogenesis. In conclusion, the downregulation of miR-193a-3p and miR-193b-3p is functionally involved in the acquisition of HPV-induced anchorage independence by targeting regulators of the PI3K-AKT pathway.

Biophysical insights into the binding capability of Cu(II) schiff base complex with BSA protein and cytotoxicity studies against SiHa

Herein, we have explored the effects of chlorinated mononuclear Cu(II) complex upon binding with BSA protein (bovine serum albumin) and its in vitro anti-proliferative potentiality against SiHa cell. The complex was synthesized involving a Schiff base ligand having N,N,O donor centers and characterized by several spectroscopic studies. Structure, DFT studies and Hirshfeld surface (HS) analyses were identified using crystallographic computational studies. The binding interaction with BSA depicts the efficacy of the complex towards promising binding of it with BSA. Further, the complex shows a moderate cytotoxicity against SiHa cancer cell signifying its potentiality as an anti-proliferative agent for human cervix uteri carcinoma.

LncRNA LINC01116 Regulates the Proliferation, Migration, and Invasion of Cervical Cancer Cells by Targeting miR-744-5p

Objective. To investigate the effects and potential molecular mechanisms of LncRNA LINC01116 on proliferation, migration, and invasion of cervical cancer cells. Method(s). The content of miR-744-5p and LINC01116 in cervical cancer cells HeLa, SiHa, and C33a was detected by RT-PCR, the proliferative activity and clone number of SiHa cells were determined by MTT and clone formation assay, the number of invaded and migrated cells was determined by Transwell assay, the expressions of Cyclin D1 and MMP-2 in cells were detected by Western blot, and the activity of luciferase detected by dual-luciferase reporting system verified the regulatory relationship between LINC01116 and miR-744-5p. Result(s). Compared with human normal cervical epithelial cells Ect1/E6E7, the content of LINC01116 in cervical cancer cells HeLa, SiHa, and C33a was increased significantly [( 1.04 ± 0.12 ) vs. ( 3.34 ± 0.38 )/( 4.48 ± 0.45 )/( 3.59 ± 0.45 )] ( P < 0.05 ), the content of miR-744-5p was decreased significantly [( 0.98 ± 0.09 ) vs. ( 0.39 ± 0.04 )/( 0.34 ± 0.05 )/( 0.41 ± 0.05 )] ( P < 0.05 ). Silencing LINC01116 could inhibit the protein expression of Cyclin D1 [( 0.68 ± 0.06 ) vs. ( 0.31 ± 0.04 )] and MMP-2 [( 0.74 ± 0.08 ) vs. ( 0.34 ± 0.05 )] in SiHa cells, and inhibition of cell proliferation [( 100.98 ± 7.89 )% vs. ( 67.26 ± 6.14 )%], clone formation ability [( 180.31 ± 11.34 ) vs. ( 53.56 ± 6.18 )], migration [( 234.67 ± 15.31 ) vs. ( 98.46 ± 7.46 )], and invasion [( 134.83 ± 9.12 ) vs. ( 62.44 ± 5.34 )]. LINC01116 targeted and negatively regulates the expression of miR-744-5p. Overexpression of miR-744-5p could inhibit the proliferation of cervical cancer SiHa cells [( 101.64 ± 4.89 )% vs. ( 62.34 ± 5.73 )%], clone formation ability [( 179.24 ± 12.34 ) vs. ( 47.67 ± 5.18 )], migration [( 241.06 ± 16.64 ) vs. ( 84.52 ± 7.57 )], and invasion [( 127.92 ± 8.16 ) vs. ( 65.24 ± 7.36 )]. Inhibition of miR-744-5p reversed the effects of silencing LINC01116 on SiHa cell proliferation [( 102.46 ± 7.64 )% vs. ( 146.72 ± 12.23 )%], clone formation ability [( 47.64 ± 6.20 ) vs. ( 104.26 ± 8.64 )], migration [( 81.52 ± 7.42 ) vs. ( 153.64 ± 12.57 )], and invasion [(69.12 ± 5.56) vs (94.31 ± 7.44)]. Conclusion(s). LncRNA LINC01116 inhibits proliferation, migration, and invasion of SiHa cells by targeting miR-744-5p, and LINC01116 is a potential molecular target for cervical cancer.

ROS -mediated anticancer response of potent copper(II) drug entities derived from S, O and N, N chelating donor scaffold: Single X-ray crystal diffraction and spectroscopic studies

New Cu(II) anticancer drug entities derived from S, O, and N, N donor chelating scaffolds were synthesized and thoroughly characterized by various spectroscopic and single X-ray diffraction studies. The single X-ray crystal structure of 1 and 2 revealed a monoclinic and triclinic crystal system with space group C 2 / c and P -1, respectively. The biomolecular interaction studies of 1 and 2 with ct-DNA were carried out by employing a battery of biophysical techniques, viz., absorption, emission, circular dichroic, and electrochemical (CV) and corroborative results of these experiments demonstrated avid electrostatic binding via surface groove. The synthesized Cu(II) complexes showed high efficacy as ROS generators involving Cu(II)/Cu(I) redox-active pair as evidenced by cleavage assay in the presence of radical scavengers. The ROS generation in the presence of copper-based complexes is considered one of the most favorable cell death mechanisms for the inhibition of cancers. In vitro anticancer activity of 1 and 2 was, therefore, evaluated against a panel of five human cancer cell lines, namely MCF-7, MDA-MB-231, Hop-62, AW1356, and SiHa, and results of cytotoxicity demonstrated good anticancer response against all tested cancerous strains with GI50 value <10 µM, except by 1 against MDA-MB-231, Hop-62 and AW1356 cell lines. Interestingly, 2 has displayed considerable cytotoxicity against MCF-7, Hop-62, and SiHa cancer cell lines even better than that of standard drug adriamycin. Furthermore, computational DFT studies validated the high binding efficacy and significant cytotoxicity of complex 2, which could be attributed to high positive charge density over the Cu(II) center.

Green Synthesis of Silver Nanoparticles Using Musa balbisiana and Their Cytotoxic Effect on HL-60 and SiHa Cancer Cells Through Clathrin-Mediated Endocytosis

Green Synthesis of Silver Nanoparticles Using Musa balbisiana and Their Cytotoxic Effect on HL-60 and SiHa Cancer Cells Through Clathrin-Mediated Endocytosis

Hydrophobicity‐induced DNA, BSA binding, and biomaterial applications of a heteroleptic Cu(II) complex

Herein, we report a new Cu(II) complex [Cu(L)(2,2′‐bipy)](ClO4) obtained from a N,N,O donor Schiff base ligand, 2‐methoxy‐6‐((piperidin‐2‐ylmethylimino)methyl)phenol (HL), and 2,2′‐bipyridine. The title complex has been characterized using FTIR, electronic (UV–Vis), electrospray ionization mass spectrometry (ESI‐MS), and single‐crystal X‐ray studies. The crystallographic studies support the chemical formula, [Cu(L)(2,2′‐bipy)](ClO4), where the metal is coordinated by the deprotonated ligand L through N,N,O atoms and by a 2,2′‐bipy molecule chelating through the N donors. Thus, the studied complex attains penta‐coordinated distorted square pyramidal geometry with ON4 atomic environment. The existence of various non‐covalent interactions such as van der Waals, hydrogen bonding, and hydrophobic interactions that are very common in protein–small molecule interaction has been identified in the present complex from Hirshfeld surface analysis. This has provoked us to examine the nature of interactions of the studied complex with DNA and BSA protein by combined theoretical and experimental approaches. The experimental results reveal the strong binding ability of the complex to CT‐DNA by the mode of partial intercalation and to BSA by the hydrophobic manner. Apart from this, the molecular docking methodology that is used as theoretical tool in the present study also supports the binding ability and binding site of the complex inside the DNA and BSA protein. Moreover, cytotoxicity of the complex has been checked against SiHa cancer cell representing the biocompatibility of the complex and signifying its use as biomaterial transplant.

LncRNA HOXD-AS1 affects proliferation and apoptosis of cervical cancer cells by promoting FRRS1 expression via transcription factor ELF1

ABSTRACT To investigate the function of lncRNA HOXD-AS1 in cervical squamous cell carcinoma (CESC) and the underlying mechanism. The expressions of HOXD-AS1 and FRRS1 were analyzed on the online software GEPIA based on CESC-related information in The Cancer Genome Atlas (TCGA). Cervical cancer cells (SiHa and Hela) were accordingly transfected with pCDNA3.1-HOXD-AS1, sh-HOXD-AS1, sh-FRRS1 or pCDNA3.1-ELF1. After cell transfection, CCK-8, EDU and flow cytometry were applied for measurement of cell vitality, quantity and apoptosis, respectively. The relationship between HOXD-AS1 and FRRS1 was predicted on the online software LncMap and further verified by RNA binding protein immunoprecipitation. Nude mice were injected with stabilized SiHa cells transfected with sh-HOXD-AS1 to assess the tumorigenic ability of HOXD-AS1 in vivo. Immunohistochemistry detected the expression of the proliferation marker Ki-67. The levels of HOXD-AS1, ELF1 and FRRS1 were measured in vivo and in vitro. HOXD-AS1 and FRRS1 were overexpressed in CESC. After transfection of sh-HOXD-AS1, sh-ELF1 or sh-FRRS1, the proliferation of SiHa and Hela cells was inhibited and their apoptosis was promoted; while HOXD-AS1 overexpression had opposite effects on CESC development. Co-transfection of sh-FRRS1 and pCDNA3.1-HOXD-AS1 could abolish the tumor suppressive effect of FRRS1 knockdown. HOXD-AS1 elevated the level of FRRS1 by binding ELF1. Furthermore, HOXD-AS1 contributed to the CESC growth in mouse models. HOXD-AS1 promotes CESC by up-regulating FRRS1 via ELF1.

Evaluation of anti-cancer potential of Excoecaria\xa0agallocha (L.) leaf extract on human cervical cancer (SiHa) cell line and assessing the underlying mechanism of action

BackgroundThe incidence of cervical cancer is increasing at an alarming rate in many countries and presently, it is the most common form of malignant cancer being reported among women in India. Development of novel approach for cervical cancer therapy, sparing healthy normal cells overcoming the limitations of prevailing therapies is of prime importance. Mangroves constitute a significant repository of medicinally important plants. Thus, in this study, we aimed to determine the anticancer activity of the mangrove Excoecaria agallocha L. leaf extracts on human cervical cancer (SiHa HPV 16+) cell line with subsequent characterization of the bioactive compounds conferring the anticancer activity and studying the probable underlying mechanism of action of the purified plant extract.ResultsThe plant extract was subjected to silica gel column chromatography and the fractions obtained were analyzed for cytotoxic activity against SiHa cells by MTT assay. One out of the three eluted fractions exhibited selective toxicity against SiHa cells with an IC50 value of 15.538 ± 0.577 µg/mL, while it had no cytotoxic effect on normal healthy human peripheral blood mononuclear cells. High-resolution liquid chromatography mass spectroscopy, coupled to electron spray ionization and diode array detection analysis, led to the structure elucidation and identification of a few pharmacologically important compounds, with Bergenin being present in the highest abundance. Fluorescence microscopy results revealed that the plant extract fraction induced LC3 puncta formation, in EGFP- SiHa cells indicating the onset of autophagy, with simultaneous stimulation of mitophagy. The plant extract also inhibited proliferation of the SiHa-smac-mCherry cells by second mitochondria-derived activator of caspase (SMAC)—induced cytochrome c dependent apoptosis, that was further confirmed with Caspase-3 activation by colorimetric assay. The GFP-dgn in SiHa cells was remarkably protected from proteasomal degradation that might upregulate the survivability of the cells significantly. Flow cytometry followed by Western blot analysis further asserted the ability of the plant extract fraction to cause cell cycle arrest of SiHa cells in the G2/M phase by significantly reducing protein expression levels of cyclin B1 and D1, decreasing Cdc2 level and simultaneously increasing p21 and p53 levels.ConclusionIt could be inferred that the aqueous extract of E. agallocha successfully decreased the proliferation of SiHa cervical cancer cells through induction of autophagy and apoptosis in a concerted manner, with simultaneous stimulation of mitophagy and G2/M phase cell cycle arrest, hinting at Bergenin being the major compound conferring the anti-cancer activity of the plant extract. Thus, isolation of the identified bioactive compounds from E. agallocha and their subsequent purification for drug development might serve as a novel medicinal approach for the treatment of cervical cancer in conjugation with existing therapeutic methods.

Exploring the Noncovalent Interactions of the Dinuclear Cu(II) Schiff Base Complex with Bovine Serum Albumin and Cell Viability against the SiHa Cancer Cell Line.

In the present study, a dinuclear bis(μ-acetate) dicopper(II) complex [Cu2L2(μ1.1-CH3COO-)2] has been synthesized from a tridentate NNO Schiff Base ligand L (L = 2,4-dibromo-6-((3-(methylamino)propylimino)methyl)phenol) and characterized by elemental, ultraviolet-visible (UV-vis), Fourier transform infrared (FTIR), 1H NMR, and electrospray ionization-mass spectrometry (ESI-MS) spectroscopic studies. The single-crystal X-ray structure, different noncovalent interactions, Hirshfeld surface analysis, and density functional theory (DFT) studies of the dinuclear complex were determined by crystallographic computational studies. The structural study exposed that the complex consists of the penta-coordinated double μ1.1-acetato-bridged dinuclear units of Cu(II), and it is a centrosymmetric dimer in which the center of inversion lies at the midpoint of two Cu(II) ions. Hirshfeld surface and DFT studies pointed out the probable potentiality of the crystal in prospective binding with the protein. This was experimentally verified by carrying out the binding interaction studies against bovine serum albumin (BSA) protein using various spectroscopic methods. It was observed that the copper(II) complex could strongly bind to BSA and could quench the intrinsic fluorescence of BSA. Further, the studied complex was appraised for cell viability studies against SiHa cancer cells. It is observed that cell viability increases with time, demonstrating the biocompatible nature of the complex.

Copper(II) complexes with NNN and NNO Schiff base ligands as efficient photodegradation agents for methylene blue, preferential BSA binder and biomaterial transplants

Herein, a monomeric copper(II) complex of the general formula [Cu(L)Cl2] (1) and a polymeric copper(II) complex bearing the formula [Cu2L/2(µ-N3)(N3)]n, (2) have been synthesized using NNN and NNO tridentate Schiff base ligands, L and L/ where L = N-((6-methoxypyridin-2-yl)methylene)(piperidin-2-yl)methane amine and L/ = 1-((3-(methylamino)propylimino)methyl)naphthalene-2-ol. Both the complexes have been characterized by single crystal X-ray diffraction and UV–Vis, FTIR, ESI-MS spectroscopic studies. The crystal structure of the complex (1) reveals a square pyramidal geometry whereas the structure of the complex (2) exhibits elongated square pyramidal geometry and the asymmetric unit of the complex contains two Cu(II) ions connected by the single µ-azido bridge. The electronic structures of the complexes are optimized by Density Functional Theory (DFT) calculations to explore their coordination stabilities and chemically reactive parameters. Besides, the Hirshfeld surfaces and two-dimensional fingerprint plot are also carried out to visualize the intermolecular interactions in the crystal of complex 1 and complex 2. Photodegradation against Methylene Blue (MB) proves the greater efficiency of complex 2 as a photodegradation agent for MB organic pollutant dye. Preferential binding studies of both the complexes towards the protein, Bovine Serum Albumin (BSA), by a series of spectroscopic techniques reveal that complex 1 strongly interacts with BSA. The spectroscopic data are well correlated by molecular docking studies. These interaction studies prompted us for cell viability studies against SiHa cancer cell to check whether the complexes may be used as biomaterial transplants or not. It is observed that the cell viability increases with time demonstrating the biocompatible nature of the complexes as well as their uses as biomaterial transplants.

A Novel Approach to Unraveling the Apoptotic Potential of Rutin (Bioflavonoid) via Targeting Jab1 in Cervical Cancer Cells.

Rutin has been well recognized for possessing numerous pharmacological and biological activities in several human cancer cells. This research has addressed the inhibitory potential of rutin against the Jab1 oncogene in SiHa cancer cells, which is known to inactivate various tumor suppressor proteins including p53 and p27. Further, the inhibitory efficacy of rutin via Jab1 expression modulation in cervical cancer has not been yet elucidated. Hence, we hypothesized that rutin could exhibit strong inhibitory efficacy against Jab1 and, thereby, induce significant growth arrest in SiHa cancer cells in a dose-dependent manner. In our study, the cytotoxic efficacy of rutin on the proliferation of a cervical cancer cell line (SiHa) was exhibited using MTT and LDH assays. The correlation between rutin and Jab1 mRNA expression was assessed by RT-PCR analysis and the associated events (a mechanism) with this downregulation were then explored via performing ROS assay, DAPI analysis, and expression analysis of apoptosis-associated signaling molecules such as Bax, Bcl-2, and Caspase-3 and -9 using qRT-PCR analysis. Results exhibit that rutin produces anticancer effects via inducing modulation in the expression of oncogenes as well as tumor suppressor genes. Further apoptosis induction, caspase activation, and ROS generation in rutin-treated SiHa cancer cells explain the cascade of events associated with Jab1 downregulation in SiHa cancer cells. Additionally, apoptosis induction was further confirmed by the FITC-Annexin V/PI double staining method. Altogether, our research supports the feasibility of developing rutin as one of the potent drug candidates in cervical cancer management via targeting one such crucial oncogene associated with cervical cancer progression.

The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells

BackgroundCSN5, a member of Cop9 signalosome, is essential for protein neddylation. It has been supposed to serve as an oncogene in some cancers. However, the role of CSN5 has not been investigated in cervical cancer yet.MethodsData from TCGA cohorts and GEO dataset was analyzed to examine the expression profile of CSN5 and clinical relevance in cervical cancers. The role of CSN5 on cervical cancer cell proliferation was investigated in cervical cancer cell lines, Siha and Hela, through CSN5 knockdown via CRISPR–CAS9. Western blot was used to detect the effect of CSN5 knockdown and overexpression. The biological behaviors were analyzed by CCK8, clone formation assay, 3-D spheroid generation assay and cell cycle assay. Besides, the role CSN5 knockdown in vivo was evaluated by xenograft tumor model. MLN4924 was given in Siha and Hela with CSN5 overexpression.ResultsWe found that downregulation of CSN5 in Siha and Hela cells inhibited cell proliferation in vitro and in vivo, and the inhibitory effects were largely rescued by CSN5 overexpression. Moreover, deletion of CSN5 caused cell cycle arrest rather than inducing apoptosis. Importantly, CSN5 overexpression confers resistance to the anti-cancer effects of MLN4924 (pevonedistat) in cervical cancer cells.ConclusionsOur findings demonstrated that CSN5 functions as an oncogene in cervical cancers and may serve as a potential indicator for predicting the effects of MLN4924 treatment in the future.

Abstract 1252: The mechanism of the drug, SHetA2, in cervical cancer cells involves growth inhibition, mitochondria damage and release of AIF to cause caspase-independent cell death

Abstract Introduction SHetA2 is an orally-bioavailable, novel small-molecule drug that is entering first in human trials for gynecologic cancers. Upon binding to three related heat shock protein A chaperones (HSPA 5, 8 and 9 genes encoding BiP, hsc70 and mortalin proteins, respectively), SHetA2 causes release of their client proteins and inhibition of mortalin import into mitochondria. The purpose of this study was to evaluate the potential of SHetA2 for cervical cancer therapy and to explore its mechanism of action. Methods: The cytotoxic effect of SHetA2 on cervical cancer cell lines, C33a, C-4 II, CaSki, ME-180 and SiHa was assessed using a MTT metabolic viability assay. The effects of SHetA2 on cell cycle arrest were evaluated by flow cytometric analysis of PI staining and western blots. SHetA2 effects on anchorage-independent growth and cell migration were analyzed using soft-agar colony formation and wound healing scratch assays, respectively. The effect of SHetA2 on mitochondria was assessed using the JC-1 dye, measurement of ATP, electron microscopy, confocal microscopy and Seahorse XF Cell Mito Stress. Result: SHetA2 significantly reduced proliferation of all cervical cell lines in time- and dose- dependent manners. This drug also inhibited anchorage-independent growth, cell migration and cell cycle progression through G1-phase cell-cycle arrest in C-33 A and CaSki, and G2- arrest in SiHa, in association with relevant alterations of cell-cycle regulatory proteins. SHetA2 significantly decreased mitochondrial membrane potential and ATP production indicating mitochondrial toxicity. Electron microscopy demonstrated mitochondrial swelling and increased autophagic vesicles in SHetA2-treated SiHa cells. Confocal microscopy using mitochondria-specific dye demonstrated loss of mitochondrial networking and structural damage. Consistent with this, our western blot results demonstrated significant downregulation in the expression of proteins involved in mitochondrial fusion indicating that SHetA2 causes inhibition of mitochondrial fusion. Metabolic studies demonstrated that SHetA2 caused attenuation of efficient oxidative phosphorylation, ATP production, and elevation of basal glycolysis. Eventual SHetA2-induced cell death was not affected by a caspase inhibitor. Further mechanistic study demonstrated translocation of apoptosis inducing factor (AIF) from the mitochondria to the nucleus, along with nuclear DNA damage. Conclusions: SHetA2 inhibits growth, migration and invasion of cervical cancer cell lines in association with cell cycle arrest and mitochondrial toxicity. SHetA2-induced mitochondrial damage in cervical cancer cell lines likely mediates release of AIF to cause cell death in a caspase-independent manner. Citation Format: Rajani Rai, Vishal Chandra, Doris M. Benbrook. The mechanism of the drug, SHetA2, in cervical cancer cells involves growth inhibition, mitochondria damage and release of AIF to cause caspase-independent cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1252.